Biotech Values

[DewDiligence]

…belatacept was compared to cylcosporine not to tacrolimus, which is used more often, considered more potent and does not harm kidney function as much.

In the “Belatacept Conversion Trial in Renal Transplantation” (http://clinicaltrials.gov/ct2/show/NCT00402168 ), the control arm was either (continued) cyclosporine or (continued) tacrolimus. However, this open-label study was merely a supporting actor in the belatacept BLA.